irbesartan

出典: meddic

イルベサルタン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/05/01 14:42:25」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
  • Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving HH.SourceaSteno Diabetes Center, Gentofte, Denmark bDivision of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands cFaculty of Health Science, University of Aarhus dNNF Center for Basic Metabolic Research eDepartment of Medical Endocrinology, University of Copenhagen, Denmark *Both authors contributed equally.
  • Journal of hypertension.J Hypertens.2013 Aug;31(8):1646-52. doi: 10.1097/HJH.0b013e328362217c.
  • OBJECTIVE: Urinary levels of renin-angiotensin-aldosterone system (RAAS) components may reflect renal RAAS activity and/or the renal efficacy of RAAS inhibition. Our aim was to determine whether urinary angiotensinogen and renin are circulating RAAS-independent markers during RAAS blockade.METHODS:
  • PMID 23743807
  • Ionic-liquid based dispersive liquid-liquid microextraction followed by high performance liquid chromatographic determination of anti-hypertensives in rat serum.
  • Rao RN, Raju SS, Vali RM.SourceAnalytical Chemistry Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 007, India. Electronic address: rnrao@iict.res.in.
  • Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.J Chromatogr B Analyt Technol Biomed Life Sci.2013 Jul 15;931:174-80. doi: 10.1016/j.jchromb.2013.05.027. Epub 2013 Jun 4.
  • A novel, simple and eco-friendly ionic liquid based dispersive liquid-liquid microextraction followed by HPLC determination of anti-hypertensive drugs viz., eprosartan, valasartan, irbesartan, losartan and telmisartan in rat serum has been developed and validated. Experimental parameters influencing
  • PMID 23797113
  • Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
  • Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM.AbstractBACKGROUND:Telmisartan, unlike other angiotensin-receptor blockers, is a partial agonist of peroxisome proliferator-activated receptor-γ, a property that has been associated with improvements in surrogate markers of cardiovascular health in small trials involving patients with diabetes. However, whether this property translates into a reduced risk of cardiovascular events and death in these patients is unknown. We sought to explore the risk of myocardial infarction, stroke and heart failure in patients with diabetes who were taking telmisartan relative to the risk of these events occurring in patients taking other angiotensinreceptor METHODS:We conducted a populationbased, retrospective cohort study of Ontario residents with diabetes aged 66 years and older who started treatment with candesartan, irbesartan, losartan, telmisartan or valsartan between Apr. 1, 2001, and Mar. 31, 2011. Our primary outcome was a composite of admission to hospital for acute myocardial infarction, stroke or heart failure. We examined each outcome individually in secondary analyses, in addition to all-cause mortality. RESULTS:We identified 54 186 patients with diabetes who started taking an angiotensinreceptor blocker during the study period. After multivariable adjustment, patients who took either telmisartan (adjusted hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74-0.97) or valsartan (adjusted HR 0.86, 95% CI 0.77-0.95) had a lower risk of the composite outcome compared with patients who took irbesartan. In contrast, no significant difference in risk was seen between other angiotensin-receptor blockers and irbesartan. In secondary analyses, we found a reduced risk of admission to hospital for heart failure with telmisartan compared with irbesartan (adjusted HR 0.79, 95% CI 0.66- 0.96), but no significant differences in risk were seen between angiotensin-receptor blockers in our other secondary analyses. INTERPRETATION:Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension. Telmisartan and val sartan may therefore be the preferred angiotensin-receptor blockers for use in these patients.
  • CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.CMAJ.2013 Jul 8. [Epub ahead of print]
  • BACKGROUND:Telmisartan, unlike other angiotensin-receptor blockers, is a partial agonist of peroxisome proliferator-activated receptor-γ, a property that has been associated with improvements in surrogate markers of cardiovascular health in small trials involving patients with diabetes. However, wh
  • PMID 23836857

和文文献

  • Irbesartan Prevents Metabolic Syndrome in Rats via Activation of Peroxisome Proliferator-Activated Receptor γ
  • Takai Shinji,Jin Denan,Miyazaki Mizuo
  • Journal of Pharmacological Sciences 116(3), 309-315, 2011
  • Irbesartan, an angiotensin-receptor blocker, is a known agonist of peroxisome proliferator-activated receptor (PPAR) γ. … In this study, thirteen-week-old spontaneously hypertensive (SHR)/NDmcr-cp rats, representing a genetic model of metabolic syndrome, were treated daily with placebo, irbesartan (30 mg/kg), valsartan (10 mg/kg), or pioglitazone (10 mg/kg) for 4 weeks. …
  • NAID 130001014461
  • Solubility, Dissolution Rate and Bioavailability Enhancement of Irbesartan by Solid Dispersion Technique
  • Boghra Rikisha Jaysukhbhai,Kothawade Pranita Chandrakant,Belgamwar Veena Shailendra,Nerkar Pankaj Padmakar,Tekade Avinash Ramrao,Surana Sanjay Javerilal
  • CHEMICAL & PHARMACEUTICAL BULLETIN 59(4), 438-441, 2011
  • … The objective of present work was to enhance the solubility and bioavailability of poorly aqueous soluble drug Irbesartan (IBS). … In conclusion, the prepared solid dispersions showed remarkable increase in solubility, dissolution rate and hence bioavailabilty of poorly water soluble drug Irbesartan. …
  • NAID 130000648960

関連リンク

Before taking irbesartan, tell your doctor and pharmacist if you are allergic to irbesartan, any other medications, or any of the ingredients in irbesartan tablets. Ask your pharmacist for a list of the ingredients. tell your ...
Easy to read patient leaflet for irbesartan. Includes indications, proper use, special instructions, precautions, and possible side effects. ... How to use irbesartan: Use irbesartan as directed by your doctor. Check the label on the ...

関連画像

 / Generika / Irbesartan Spirig HCIRBESARTAN AL 150 mg, 98 St - shop APROVEL IRBESARTAN TABS 150MG 28 | ARDC Irbesartan STADA 75 mg Filmtabletten IRBESARTAN TAB 300 mg - MEDICAMENTOS MARCA Start > IRBESARTAN/HCT AL 300 mg/12,5 mg


★リンクテーブル★
リンク元イルベサルタン

イルベサルタン」

  [★]

irbesartan
アバプロ(大日本住友製薬)、イルベタン(塩野義)、アイミクス配合
アンジオテンシンII受容体拮抗薬降圧薬
  • 長時間作用型ARBとされる。




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡